Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CUE · as of Jun 9, 2026
Activity summary
Buy transactions
5
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Cue Biopharma, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CUE insider buying and selling by quarter
CUE insider selling · CUE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · CUE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CUE executive sell shares · CUE board member insider trading · CUE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 3, 2026 | Lin Shao-Lee CHIEF EXECUTIVE OFFICER · Director | Award | 327,537 | — | Form 4 |
| Dec 30, 2025 | Sarraf Pasha Director | Purchase | 77,417 | $23K | Form 4 |
| Dec 30, 2025 | Sarraf Pasha Director | Purchase | 78,116 | $24K | Form 4 |
| Dec 30, 2025 | Sarraf Pasha Director | Purchase | 86,947 | $28K | Form 4 |
| Dec 30, 2025 | Sarraf Pasha Director | Purchase | 77,148 | $23K | Form 4 |
| Dec 30, 2025 | Sarraf Pasha Director | Purchase | 4,229 | $1K | Form 4 |
| Dec 16, 2024 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER · Director | Purchase | 30,000 | $31K | Form 4 |
| Aug 25, 2023 | Suri Anish PRESIDENT AND CSO | Purchase | 4,000 | $11K | Form 4 |
| Aug 14, 2023 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER · Director | Purchase | 3,000 | $9K | Form 4 |
| Mar 23, 2023 | Kiener Peter A Director | Option | 9,682 | $28K | Form 4 |
| Mar 23, 2023 | Kiener Peter A Director | Sale | 9,325 | $31K | Form 4 |
| Aug 21, 2022 | Millar Kerri-Ann CHIEF FINANCIAL OFFICER | Other | 2,828 | $9K | Form 4 |
| Jun 14, 2022 | Gray Cameron Director | Other | 61,111 | $165K | Form 4 |
| Jun 14, 2022 | Gray Cameron Director | Other | 51,562 | $165K | Form 4 |
| May 27, 2022 | Morich Frank Director | Purchase | 28,000 | $105K | Form 4 |
Lin Shao-Lee
CHIEF EXECUTIVE OFFICER · Director
Date
May 3
Shares
327,537
Price
—
Value
—
PASSERI DANIEL R
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 16
Shares
30,000
Price
$1.03
Value
$31K
PASSERI DANIEL R
CHIEF EXECUTIVE OFFICER · Director
Date
Aug 14
Shares
3,000
Price
$2.86
Value
$9K
Millar Kerri-Ann
CHIEF FINANCIAL OFFICER
Date
Aug 21
Shares
2,828
Price
$3.05
Value
$9K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CUE insider trading
CUE insider trades
Cue Biopharma, Inc. (CUE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Sarraf Pasha (Director), Lin Shao-Lee (CHIEF EXECUTIVE OFFICER · Director). Over the past 12 months, 2 insiders have filed transactions with the SEC. CUE insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Cue Biopharma, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CUE insider trading · 5 questionsThe insiders of Cue Biopharma, Inc. (CUE) include executives and directors such as Sarraf Pasha (Director), Lin Shao-Lee (CHIEF EXECUTIVE OFFICER · Director), among others. Over the past 12 months, 2 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026